Re-Assert Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.60 M
- Company Age 5 Year, 30 Days
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 73.80%
- Profit Growth 141.45%
- Ebitda 151.28%
- Net Worth 71.68%
- Total Assets 91.52%
About Re-Assert Pharma
Re-Assert Pharma Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 January 2020 (Five years 30 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.60 M, as per Ministry of Corporate Affairs (MCA) records.
Atul Kamble and Neeraj Singh serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24299MH2020PTC336673
- Company No.
336673
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jan 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Re-Assert Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Kamble  | Director | 27-Jan-2020 | Current |
| Neeraj Singh | Director | 27-Jan-2020 | Current |
Financial Performance of Re-Assert Pharma.
Re-Assert Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 73.8% increase. The company also saw a substantial improvement in profitability, with a 141.45% increase in profit. The company's net worth Soared by an impressive increase of 71.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Re-Assert Pharma?
In 2023, Re-Assert Pharma had a public holding of 80.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Re-Assert Pharma?
Unlock and access historical data on people associated with Re-Assert Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Re-Assert Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Re-Assert Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.